SecBot SecBot
PRESS-RELEASE ·Filed Apr 20, 2026

PASG

Passage Bio
MIXED
Impact 6/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ◆ Mixed

Monitor for updates on the strategic review outcome, as this may determine whether shareholders realize value through a sale or face dilution from a costly registrational trial. The biomarker data is encouraging, but the FDA's stance increases development risk significantly.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.25
T+0 close · Apr 20, 2026 · via day close
Latest settled
−21.44%
T+60 · $4.91
Vs SPY
−28.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $6.25entry
  2. T+1 · 7mo ago −1.12%α −0.47% · $6.18
  3. T+5 · 7mo ago −8.64%α −9.55% · $5.71
  4. T+20 · 6mo ago −18.08%α −22.28% · $5.12
  5. T+60 · 4mo ago −21.44%α −28.22% · $4.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Passage Bio reported updated Phase 1/2 data showing PBFT02 reduced brain atrophy and stabilized plasma NfL in early-stage FTD-GRN patients, but the FDA has mandated a randomized controlled trial for approval, creating ethical and financial hurdles. The company has initiated a strategic review to evaluate alternatives, including a potential sale or partnership, amid development challenges.

Key Facts

  • PBFT02 reduced whole brain atrophy by 64% and frontotemporal cortex atrophy by 54% in CDR 1 patients vs. natural history.
  • Plasma NfL levels stabilized in treated patients vs. significant increase in untreated natural history cohort.
  • FDA requires a randomized controlled trial for registrational approval, rejecting a single-arm design.
  • Company has initiated a strategic review of alternatives, including M&A, asset sale, or licensing, with Wedbush PacGrow as advisor.

Financial Impact

No immediate financial impact disclosed; strategic review may lead to monetization or dilution depending on outcome.

cash runwaydilutionstrategic value

Risk Factors

  • High cost and ethical challenges of conducting a randomized controlled trial in a rare, rapidly progressing disease.
  • Strategic review may not yield a transaction, leaving the company underfunded for late-stage development.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276853

Track record

15 reports on PASG

Performance horizon

2 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
  2. Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
  3. Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
  4. Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
  5. Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
  6. Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
  8. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  9. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  10. Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 20, 2026